Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571060 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial in Adult Participants With Acute Migraines
A Phase 3 study of Migraine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,978
- Enrollment target
- 20
- Study locations
NCT04571060 is a Phase 3 study of Migraine that has completed, run by Pfizer. The registered enrollment target is 1,978 participants, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (483% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT04571060, a Phase 3 study of Migraine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,978 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zavegepant
Study Locations (20)
California
- Axiom Research, LLC - Colton
- Pharmacology Research Institute - Encino
- eStudySite - La Mesa
- Synergy San Diego - Lemon Grove
- Collaborative Neuroscience Network, LLC - Long Beach
- Pharmacology Research Institute - Los Alamitos
- Clinical Research Institute - Los Angeles
- Wr-Pri, Llc - Newport Beach
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
- California Neuroscience Research Medical Group, Inc. - Sherman Oaks
Alabama
- Medical Affiliated Research Center - Huntsville
- Coastal Clinical Research, LLC, An AMR Co. - Mobile
Arizona
- MD First Research - Chandler
- Tucson Neuroscience Research - Tucson
Connecticut
- CT Clinical Research - Cromwell
- Ki Health Partners, LLC dba New England Institute for Clinical Research - Stamford
Florida
- Neurology Offices of South Florida - Boca Raton
- Clinical Neuroscience Solutions, Inc. - Jacksonville
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,978 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04571060
The ClinicalTrials.gov registry entry for NCT04571060 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,978 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 339-participant average among 102 other Migraine trials with a reported enrollment target (483% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04571060 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04571060 about?
NCT04571060 is a clinical study titled "Randomized Trial in Adult Participants With Acute Migraines". The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
What is the current status of trial NCT04571060?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,978 participants. The study started on 2020-10-27. Estimated completion is 2021-10-22.
What conditions does trial NCT04571060 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT04571060?
The interventions under investigation include: Placebo (DRUG), Zavegepant (DRUG).
Who is sponsoring clinical trial NCT04571060?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04571060 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.